Following an earlier bacterial vaccine development collaboration, AstraZeneca has acquired partner Omniose for an undisclosed amount, with the biotech becoming a wholly-owned subsidiary of the UK drugmaker's infectious disease unit. "Omniose's bioconjugation platform represents a differentiated approach to engineering conjugate vaccines and strengthens our ability to develop novel vaccines against serious bacterial infections," said Benjamin Moutier, AstraZeneca's SVP of infectious disease. The

Hangzhou Eli Radiopharma concluded a series A round, raising nearly RMB 400 million ($60 million), to propel its oncology- and neurology-directed radiopharmaceutical assets into clinical development. "Moving our pipeline toward the clinic is a critical next step in translating our research into meaningful advances for patients," said Eli Radiopharma CEO and founder Feng Yu. "We remain focused on addressing unmet clinical needs and strengthening our R&D and clinical development capabilities." The

The proceeds will also fund the expansion of the company’s neurodegeneration programmes. Credit: H_Ko/Shutterstock.com. Delix Therapeutics has secured $100m in an oversubscribed Series C financing round to fund the development of zalsupindole (DLX001), an orally bioavailable neuroplastogen. The company will advance zalsupindole into Phase II development and finance a broader pipeline expansion. The drug is being designed to treat psychiatric and psychological disorders. In animal models, single

RMAT designation provides early and frequent FDA engagement to support planned pivotal development of Senza5 CART5 Therapy may be eligible for priority review and accelerated approval if applicable criteria are met Orphan Drug Designation, granted in July 2026, provides development incentives to support Senza5 CART5 in T-cell lymphoma Nov. 10, 2026 -- Vittoria Biotherapeutics, Inc. (“Vittoria” or the “Company”), a clinical-stage immunotherapy company developing engineered T-cell therapies, tod

The FDA has approved Merck KGaA's oral CSF-1R inhibitor Pimjetmi (pimicotinib) for adults with symptomatic tenosynovial giant cell tumour (TGCT) for whom surgical removal could cause worsening functional limitations or severe morbidity. The decision gives the German drugmaker another major market for the treatment, following approvals in China, Canada and Switzerland. TGCT is a rare, usually benign tumour arising from the synovium of joints, tendon sheaths and bursae. While it doesn't typically

Trial designed to improve outcomes through Signatera™-guided Treatment on MRD (TOMR), identifying high-risk patients for curative-intent treatment Natera, Inc. (Nasdaq:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has entered into a clinical collaboration agreement with Incyte (Nasdaq:INCY) for a new phase II study in colorectal cancer (CRC). The trial will evaluate INCA33890, Incyte’s investigational bispecific immunotherapy, in patients with stage 2/

Breakthrough Therapy designation granted based on FDA’s review of safety and efficacy data from the chronic cohort of the Phase 1b/2a CONNECT SCI study Phase 3 RESTORE registrational study enrolling participants, with site activation continuing in the United States and Canada Nov. 12, 2026 -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic condition

Financing will support Phase II development of Zalsupindole on the back of strong Phase Ib results Funding will also further advancement of other programs in Delix’s neuroplastogen pipeline, including additional clinical trials and continued asset-specific pipeline expansion into neurological and neurodegenerative diseases Representatives of both lead investors will join Delix’s Board of Directors Delix Therapeutics, a clinical-stage neuroscience company pioneering the discovery and development

Following a crushing Phase III defeat in atrial fibrillation (AF) three years ago, Bayer's asundexian has now become the first approved factor XIa inhibitor in the US following an FDA nod Monday in secondary stroke prevention. The once-daily oral drug, which will be sold as Sunharbo, is indicated for use in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack (TIA). "This FDA approval r

FDA feedback supports planned bioequivalence-based 505(b)(2) development pathway for once-daily treprostinil prodrug patch Corsair Pharma, Inc., a private, clinical-stage biopharmaceutical company developing prodrug-based transdermal medicines to improve the delivery and therapeutic pro established therapies, today announced a positive outcome from its pre-investigational new drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for the TRX-248 Transdermal System, a treprostin